No Data
No Data
No Data
No Data
No Data
Navigating Uncertainty: How Healthcare Reforms Pose Risks to Revelation Biosciences Inc.
TipRanksMar 24 14:00
Revelation Biosciences Q4 EPS $(8.33) Beats $(13.77) Estimate
Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(8.33) per share which beat the analyst consensus estimate of $(13.77) by 39.51 percent. This is a 84.31 percent increase over losses
BenzingaMar 23 04:22
Press Release: Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023 SAN DIEGO--(BUSINESS WIRE)--March 22, 2024-- Revelation Biosciences, Inc. (NASDAQ: RE
Dow JonesMar 23 04:15
Revelation Biosciences 4Q Loss/Shr $8.33 >REVB
Revelation Biosciences 4Q Loss/Shr $8.33 >REVB
Dow JonesMar 23 04:15
Revelation Biosciences Sees Funding Sufficient Through 2024 >REVB
Revelation Biosciences Sees Funding Sufficient Through 2024 >REVB
Dow JonesMar 23 04:15
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersGeron (NASDAQ:GERN) stock increased by 90.8% to $3.34 during Thursday's after-market session. The market value of their outstanding shares is at $1.8 billion. Madrigal Pharmaceuticals (NASDAQ:M
BenzingaMar 15 05:33
No Data
No Data